Publications by authors named "Liliana Patrucco"
Article Synopsis
- - The study aimed to analyze how myelin oligodendrocyte glycoprotein-associated antibody disease (MOGAD) affects employment among adults internationally by measuring job loss, hours worked, and wages.
- - Researchers gathered data from 117 adults diagnosed with MOGAD across 13 countries, finding a decline in employment from 63.2% before diagnosis to 48.7% after, and a drop in average work hours from 31.6 to 19.5 hours per week.
- - Results showed that living in a high-income country was linked to better employment outcomes post-MOGAD, while factors like depressed mood and pain were associated with increased unemployment and reduced work hours.
Background: We assessed the effectiveness, safety and patient-reported outcomes (PROs) of dimethyl fumarate (DMF) in real-world clinical practice in patients with multiple sclerosis (PwMS) from Argentina.
Methods: We conducted a multicenter ambispective cohort study in Argentina between September 2020 and March 2023. Changes in annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, magnetic resonance imaging (MRI), no evidence of disease activity (NEDA), PROs (depression, anxiety, fatigue, burden of treatment and quality of life), and safety data were collected at clinical visits performed every 6 months for at least 24 months.
Article Synopsis
- Immunosuppressive therapies like azathioprine (AZA), mycophenolate mofetil (MMF), and rituximab (RTX) are used to prevent relapses in NMOSD, but response rates specifically in Argentina were previously unknown.
- A retrospective study analyzed 139 NMOSD patients from the RelevarEM registry, tracking their response to these treatments over a mean follow-up of 41.3 months, revealing that RTX had a significantly lower treatment failure rate compared to AZA and MMF.
- The study found treatment failures were 42.8% for AZA, 40% for MMF, and only 10.3% for RTX, indicating that higher efficacy treatments like RTX
Article Synopsis
- The study evaluated the effectiveness and safety of cladribine (CLAD) for treating relapsing-remitting multiple sclerosis in 240 patients across Argentina, focusing on clinical relapses and disease progression over 24 months.
- Results showed a significant decrease in annual relapse rates from 1.19 to 0.19, with many patients achieving no evidence of disease activity (NEDA) at both 12 months (84.2%) and 24 months (77%).
- The study also monitored lymphopenia, finding that grade 1 lymphopenia was the most common, while severe grade 4 lymphopenia was rare, suggesting CLAD is a safe treatment option.
Unlabelled: We aimed to assess the treatment strategies utilized in patients with neuromyelitis optica spectrum disorder (NMOSD) experiencing relapses, including their frequency, types, and response after 6 months based on the Expanded Disability Status Scale (EDSS) score.
Methods: We conducted a retrospective study involving NMOSD patients from the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177). Treatment response at 6 months was categorized as "good" if the EDSS score decreased by ≥1 point after a nadir EDSS score ≤ 3, or by ≥2 points after a nadir EDSS score > 3, "poor" if the EDSS score decrease was slighter, and as "absent" if the EDSS score remained unchanged or worsened.
Background: Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is to evaluate the choice of DMTs in pwMS older than 50 years old in a real-world setting.
Methods: Cross-sectional study of pwMS from the Argentine MS and NMOSD Registry.
Article Synopsis
- The study examined the occurrence, duration, and severity of area postrema syndrome (APS) in patients with neuromyelitis optica spectrum disorder (NMOSD) across several Latin American countries.
- A total of 116 out of 631 patients (18.3%) experienced APS, with severe symptoms being the most common, and the average symptom duration was about 10 days, often treated effectively with IV steroids.
- The research found that inflammatory activity significantly decreased after APS onset, but no specific factors were linked to the severity of the syndrome.
Unlabelled: The objective of this study was to describe and compare the burden of treatment (BOT) and the quality of life (QoL) in early high efficacy therapy (HET) vs. escalation therapy in relapsing remitting multiple sclerosis (RRMS) patients included in RelevarEM, the Argentinean registry of MS (RelevarEM, NCT 03,375,177).
Methods: cross sectional study conducted between September and December 2022.
Background And Objectives: Primary-progressive multiple sclerosis (PPMS) is characterized by gradual neurological deterioration without relapses. This study aimed to investigate the clinical impact of gender and age at disease onset on disease progression and disability accumulation in patients with this disease phenotype.
Methods: Secondary data from the RelevarEM registry, a longitudinal database in Argentina, were analyzed.
Background: Most Multiple Sclerosis (MS) clinical trials fail to assess the long-term effects of disease-modifying therapies (DMT) or disability.
Methods: COLuMbus was a single-visit, cross-sectional study in Argentina in adult patients with ≥10 years of MS since first diagnosis. The primary endpoint was to determine patient disability using the Expanded Disability Status Scale (EDSS).
Article Synopsis
- The study assessed the occurrence of SARS-CoV-2 breakthrough infections in vaccinated people with multiple sclerosis (PwMS) receiving high-efficacy disease-modifying therapies (HET) in Argentina.
- The analysis involved 228 adult PwMS who were fully vaccinated with vaccines like AstraZeneca and Sputnik, primarily receiving cladribine as their HET.
- The results indicated a breakthrough infection rate of 3.5 cases per 10,000 patients per day, with higher risks observed in patients treated with ocrelizumab compared to other therapies.
We aimed to evaluate mortality and causes of death among Argentinean neuromyelitis optica spectrum disorder (NMOSD) patients and identify predictors of death. Retrospective study included 158 NMOSD patients and 11 (7%) patients died after 11 years of follow-up for a total exposure time of 53,345 days with an overall incidence density of 2.06 × 10.
View Article and Find Full Text PDFArticle Synopsis
- Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are classified by their effectiveness, with high-efficacy treatments (HETs) having limited data in Latin America, particularly Argentina.
- A study using the RelevarEM registry found that 19% of 2,450 patients with relapsing-remitting MS (RRMS) were on HETs, with many switching due to treatment failures, leading to a significant increase in HET usage from 11.65% to 29.55% over two time periods.
- The research highlighted rapid growth in HET adoption, with the most common treatments being alemtuzumab and cladribine, and emphasized understanding the demographics
Article Synopsis
- A study was conducted to evaluate how often new asymptomatic MRI lesions appear in patients with neuromyelitis optica spectrum disorder (NMOSD) and if these lesions correlate with later relapses.
- Researchers reviewed 675 MRI scans from 135 NMOSD patients, finding that nearly 20% had new lesions during relapse-free periods, while almost 49% showed new lesions during attacks.
- Despite these findings, new asymptomatic lesions did not predict a faster onset of subsequent relapses, indicating their occurrence may not impact disease progression.
Introduction: The objective was to assess the immunogenicity and effectiveness of vaccines against SARSCoV-2 in multiple sclerosis (MS) patients included in the Argentinean MS registry.
Methods: A prospective cohort study between May and December 2021. The primary outcome was immunogenicity and effectiveness of vaccines during a three-month follow-up.
Background: Optic neuritis (ON) can be an initial manifestation of neuromyelitis optica spectrum disorder (NMOSD) associated with aquaporin 4-antibody (AQP4-Ab) or myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated disease (MOGAD). Additionally, both diseases may have overlapping paraclinical and radiological features. These diseases may have different outcomes and prognoses.
View Article and Find Full Text PDFBackground: We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years.
Methods: This retrospective cohort study based on Argentina Multiple Sclerosis patient registry (RelevarEM), includes highly active multiple sclerosis patients who received HETs.
Results: In total, 254 (78.
Purpose: This study describes the therapeutic strategies in NMOSD and MOGAD adopted by neurologists to treat both conditions in Latin America (LATAM) with main focus on rituximab (RTX) and the disease outcome.
Methods: retrospective study in a cohort of NMOSD and MOGAD patients followed in specialized MS/NMOSD centers from eight countries and 14 LATAM reference centers. Demographics and clinical characteristics were collected.
Objectives: We aimed to determinate the frequency of this association and compare the features of neuromyelitis optica spectrum disorder (NMOSD) with and without associated autoimmune diseases (AD) in a Latin American (LATAM) population in clinical practice.
Methods: We retrospectively reviewed the medical records of patients with NMOSD according to the 2015 diagnostic criteria. Patients from Argentina (n=77), Brazil (n=46), and Venezuela (n=17) were enrolled and classified into two groups as follows: with AD or without AD.
Background: The use of telemedicine has quickly increased during of the COVID-19 pandemic. Given that unmet needs and barriers to multiple sclerosis (MS) care have been reported, telemedicine has become an interesting option to the care of these patients. The objective of these consensus recommendations was to elaborate a guideline for the management of people with MS using telemedicine in order to contribute to an effective and high-quality healthcare.
View Article and Find Full Text PDFBackground: The percentage of brain volume loss (PBVL) has been classically considered as a biomarker in multiple sclerosis (MS).
Objective: The objective of the present study was to analyze if the PBVL during the 1 year after the onset of the disease predicts physical and cognitive impairment (CI).
Methods: Prospective study that included naïve patients without cognitive impairment who initiated MS treatment with fingolimod.
Introduction: The discontinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS) is commonly seen in real-world settings due to several factors.
Area Cover: The aim of this study is to describe the frequency of disease activity after discontinuation of DMTs in MS patients included in the Argentinean MS and NMOSD registry.
Discusion: Patients with relapsing remitting MS (RRMS) and active secondary progressive MS (SPMS) were included based on the following criteria: they discontinued treatment for more than 6 months, they had been treated with a DMT for ≥2 years, and they had at least 6 months of follow-up in the registry after discontinuation.
Unlabelled: The objective was to evaluate time to reach an EDSS of 4, 6, and 7 in NMOSD and MOGAD patients included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03,375,177).
Methods: NMOSD patients diagnosed according to 2015 criteria and with MOGAD were identified. Patients with at least 3 years of follow-up and periodic clinical evaluations with EDSS outcomes were included.
Unlabelled: The objective of the study was to evaluate the incidence of COVID-19 after complete vaccination in people with multiple sclerosis (PwMS) included in the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177).
Methods: cohort study conducted between May 2021 and December 2021. The primary outcome was the appearance of infection during the follow-up time (at least three months after complete vaccination (second dose)).